Agreement to build on research and technical expertise in characterizing methylation patterns in lung cancer
SAN DIEGO & REHOVOT, Israel–(BUSINESS WIRE)– Nucleix a liquid biopsy company that is revolutionizing cancer treatment by detecting the disease earlier has entered into a research collaboration and licensing agreement with: The University of Texas MD Anderson Cancer Center evaluating and developing methylation assays targeting lung cancer, using Nucleix’s highly sensitive EpiCheck® platform.
The collaboration will initially focus on evaluating methylation markers believed to be important for characterization of lung cancer subtypes. Selected markers will be evaluated using EpiCheck – Nucleix’s proprietary platform, which can be performed with both PCR and next-generation sequencing technologies, and has demonstrated the best analytical sensitivity.
For those markers that demonstrate efficacy in aiding this characterization, Nucleix will lead the development of new tests. MD Anderson will work on validating tests using: in vitro and in vivo cell lines, preclinical models and clinical samples.
“As described in a recent publication in the European Respiratory Diary, our Lung EpiCheck® test is highly sensitive and has the potential to aid in the early detection of lung cancer in high-risk individuals, but we know there is also a great need for patients who have already been diagnosed and are undergoing treatment. undergone,” said Chris Hibberd, chief executive officer of Nucleix. “By partnering with MD Anderson, we aim to expand the methylation tools available for assessment and care for this patient population.”
Nucleix’s Lung EpiCheck test analyzes changes in methylation patterns for early detection of lung cancer. The company is focused on advancing the test for the approximately 15 million high-risk smokers eligible for annual screening. In a recently published studyThe test detected 85% of early-stage lung cancers in individuals at high risk of developing the disease based on their smoking history.
“Blood-based methylation tests are minimally invasive and can provide important information about a patient’s lung cancer that cannot be provided by standard genomic profiling of DNA mutations, allowing physicians to better identify disease subtypes and emerging biomarkers in the clinic,” said John V. Heymach, MD, Ph.D., chair of thoracic/head and neck medical oncology at MD Anderson. “We look forward to partnering with Nucleix to improve methylation measurement tools, with the goal of enabling physicians to provide more personalized, biomarker-driven treatment approaches for our patients.”
EpiCheck® is an ultra-sensitive technology for the detection of methylation changes and is compatible with next-generation sequencing (NGS) and polymerase chain reaction (PCR) platforms. Nucleix applies EpiCheck’s NGS application for in-depth discovery, to reveal novel biomarkers that can be used in the early detection and monitoring of cancer. These discoveries, in turn, can be developed as highly sensitive tests using EpiCheck’s PCR application, with the potential to be performed cost-effectively in both centralized and local labs.
Nucleix is a liquid biopsy company that is revolutionizing cancer treatment with earlier disease detection at a time when intervention can have the greatest impact for patients. By leveraging NGS and PCR-based epigenetics, the company’s pioneering testing approach leverages methylation-based identification for early and recurrent cancer detection. The company’s non-invasive EpiCheck® platform delivers highly accurate and sensitive results, while providing a seamless testing option for patients and the healthcare system. The company is building an EpiCheck franchise, starting with the Bladder EpiCheck® test kit, which is being marketed in Europe for bladder cancer recurrence. The company is advancing a Lung EpiCheck test toward commercialization for high-risk individuals, while advancing additional testing for high-risk disease. For more information, visit: https://www.nucleix.com.